A multicenter large-sample survey on adverse events of focused ultrasound ablation surgery for benign uterine diseases in clinical training and teaching hospitals
Other
public-domain-us
Abstract
OBJECTIVE: To evaluate the adverse events and complications associated with focused ultrasound ablation surgery(FUAS)for benign uterine diseases in teaching and training centers.
MATERIALS AND METHODS: From October 2010 to December 2023, 26,844 patients with benign uterine diseases were treated with FUAS and more than 2000 doctors had been trained in three teaching and training centers. Among the treated patients, 16,619 had uterine fibroids, 8732 had adenomyosis, 1154 had cesarean scar pregnancy, and 379 had placental accreta spectrum. According to the classification system of the Society of Interventional Radiology (SIR), these adverse events were classified as mild adverse event (no therapy or nominal therapy), moderate adverse event (moderate escalation of care, requiring substantial treatment), severe adverse event (marked escalation of care), Life-threatening or disabling event, and patient death or unexpected pregnancy abortion.
RESULTS: Mild adverse effects occurred in 2,352 (8.75%) patients, moderate adverse events were seen in 147 (0.55%) patients, severe adverse events encountered in 50 (0.18%) patients. No life-threatening or disabling event, and patient death or unexpected pregnancy abortion occurred. The overall incidence rate of severe adverse events was 0.18% (n = 50). From 2010 to 2023, the annual incidence rates of severe adverse events were 0%, 0.42%, 0%, 0%, 0.28%, 0.23%, 0.09%, 0.08%, 0.20%, 0.28%, 0.44%, 0.16%, 0.16%, and 0.10%, respectively.
CONCLUSION: Based on the results, we concluded that FUAS is a safe treatment for benign uterine diseases. The training course for trainee did not increase the risk of severe adverse events.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-11-18T06:10:28.346261+00:00
- pubmed
- last seen: 2026-11-18T06:04:25.516603+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine